Differential Effect of JAK1/2 and TYK2 Inhibitors on Type III Interferon Induced Antiviral Defence in Human Intestinal Epithelial Cells
Immune System · 2024
DOI: 10.1159/000538571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immune System, 2024. Verfasst von Martha A. Castro und 4 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Many cytokines, acting via Janus kinase (JAK)/tyrosine kinase 2 (TYK2)/signal transducer and activator of transcription (STAT) signalling pathways, are critical mediators of pathology in immune-mediated inflammatory diseases (IMIDs). Therefore, drugs that inhibit JAKs and TYKs (JAKis) have gained traction as effective treatment options for IMIDs. However, a common side effect of JAKis is increased risk of viral infection. Type I and III interferon (IFN) signal via JAK1 and TYK2. Type III IFNs protect mucosal membranes, including the intestinal barrier, from viral infection and type I IFNs prevent systemic viral spread.
Methods
The human cell lines Caco-2 and HT-29 were used to investigate the impact of currently approved JAKis, baricitinib (JAK1/2 inhibitor) and deucravacitinib (TYK2 inhibitor), on type I and III IFN signalling and antiviral defence of intestinal epithelial cells (IECs).
Results
Using concentrations commonly used for in vitro studies on IFNs, we found that attenuation of IFN-mediated antiviral defence in IECs is a mechanism that could contribute to the increased risk of viral infections associated with JAKis. However, when we examined clinically relevant drug concentrations, we found that while both drugs blocked the type I IFN response, type III IFN-induced antiviral immunity was less affected during TYK2 inhibition (deucravacitinib) compared to JAK1/2 inhibition (baricitinib).
Conclusions
Our studies suggest that in treating diseases associated with excessive cytokine production (e.g., type I IFNs, interleukin (IL)-6, and IL-23), a TYK2 inhibitor may be preferable over a JAK1/2 inhibitor. This preference arises as the TYK2 inhibitor can effectively block the activity of proinflammatory and tissue-damaging cytokines (e.g., type I IFNs), while having less negative impact on the intestine’s ability to respond to type III IFN, thereby enabling it to enter an antiviral state.
Zitieren
APA
Castro, M. A., Ringqvist, E. E., Parajuli, A., Stone, V. M., & Flodström-Tullberg, M. (2024). Differential Effect of JAK1/2 and TYK2 Inhibitors on Type III Interferon Induced Antiviral Defence in Human Intestinal Epithelial Cells. Immune System. https://doi.org/10.1159/000538571
Vancouver
Castro MA, Ringqvist EE, Parajuli A, Stone VM, Flodström-Tullberg M. Differential Effect of JAK1/2 and TYK2 Inhibitors on Type III Interferon Induced Antiviral Defence in Human Intestinal Epithelial Cells. Immune System. 2024. doi:10.1159/000538571
BibTeX
@article{Castro2024,
author = {Castro, Martha A. and Ringqvist, Emma E. and Parajuli, Anirudra and Stone, Virginia M. and Flodström-Tullberg, Malin},
title = {Differential Effect of JAK1/2 and TYK2 Inhibitors on Type III Interferon Induced Antiviral Defence in Human Intestinal Epithelial Cells},
journal = {Immune System},
year = {2024},
doi = {10.1159/000538571}
}
EUVIMED